‘New GSK’ Still Has Some Convincing To Do

Vaccine And Speciality Medicines The Focus

Once the consumer health division is spun out in mid-2022, a leaner ‘new GSK’ must set about delivering on its promising pipeline – and proving its skeptics wrong.

GSK syringes
The 'New GSK' aims to deliver growth from its vaccines and speciality medicines pipeline, plus a steady but flat income from established general medicines. • Source: Alamy

More from Business

More from Scrip